Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial

Arthur A.M. Bookman, Kate S.A. Williams, J. Zev Shainhouse

Abstract

**Background:** Treatment of osteoarthritis with oral NSAID therapy provides pain relief but carries a substantial risk of adverse effects. Topical NSAID therapy offers an alternative to oral treatment, with the potential for a reduced risk of side effects. The objective of this trial was to assess the safety and efficacy of a topical diclofenac solution in relieving the symptoms of primary osteoarthritis of the knee.

**Methods:** We identified 248 men and women from southern Ontario with primary osteoarthritis of the knee and at least moderate pain. The patients were randomly assigned to apply 1 of 3 solutions to their painful knee for 4 weeks: a topical diclofenac solution (1.5% wt/wt diclofenac sodium in a carrier containing dimethyl sulfoxide [DMSO]); a vehicle-control solution (the carrier containing DMSO but no diclofenac); and a placebo solution (a modified carrier with a token amount of DMSO for blinding purposes but no diclofenac). The primary efficacy end point was pain relief, measured by the Western Ontario and McMaster Universities (WOMAC) LK3.0 Osteoarthritis Index pain subscale. Secondary end points were improved physical function and reduced stiffness (measured by the WOMAC subscales), reduced pain on walking and patient global assessment (PGA). Safety was evaluated with clinical and laboratory assessments.

**Results:** In the intent-to-treat group the mean change (and 95% confidence interval [CI]) in pain score from baseline to final assessment was significantly greater for the patients who applied the topical diclofenac solution (−3.9 [−4.8 to −2.9]) than for those who applied the vehicle-control solution (−2.5 [−3.3 to −1.7]; p = 0.023) or the placebo solution (−2.5 [−3.3 to −1.7]; p = 0.016). For the secondary variables the topical diclofenac solution also revealed superiority to the vehicle-control and placebo solutions, leading to mean changes (and 95% CIs) of −11.6 (−14.7 to −8.4; p = 0.002 and 0.014, respectively) in physical function, −1.5 (−1.9 to −1.1; p = 0.015 and 0.002, respectively) in stiffness and −0.8 (−1.1 to −0.6; p = 0.003 and 0.015, respectively) in pain on walking. The PGA scores were significantly better for the patients who applied the topical diclofenac solution than for those who applied the other 2 solutions (p = 0.039 and 0.025, respectively). The topical diclofenac solution caused some skin irritation, mostly minor local skin dryness, in 30 (36%) of the 84 patients, but this led to discontinuation of treatment in only 5 (6%) of the cases. The incidence of gastrointestinal events did not differ between the treatment groups. No serious gastrointestinal or renal adverse events were reported or detected by means of laboratory testing.

**Interpretation:** This topical diclofenac solution can provide safe, site-specific treatment for osteoarthritic pain, with only minor local skin irritation and minimal systemic side effects.
ate pain during the 2 weeks before random assignment to treatment, as identified with the Western Ontario and McMaster Universities (WOMAC) LK3.0 Osteoarthritis Index pain subscale; age 18 to 80 years; and, if female, could not or would not become pregnant. Exclusion criteria were as follows: secondary arthritis related to syphilitic neuropathy, ochronosis, metabolic bone disease or acute trauma; sensitivity to diclofenac, ASA or any other NSAID, DMSO, propylene glycol, glyc erin or ethanol; clinically active renal, hepatic or peptic ulcer disease; history of alcohol or drug abuse; lactation; concomitant skin disease at the application site; corticosteroid use; use of another topical product at the application site; and oral use of an analgesic or glucosamine. Patients using NSAIDs or other prohibited medications underwent a 1-week washout of that medication before baseline assessment and random assignment to treatment. (This was a nonfla re study: an increase [flare] in pain after washout of previous medication was not required.) The use of ASA (≤325 mg/d) was permitted for cardiovascular prophylaxis.

Patients were randomly assigned to receive treatment with 1 of 3 solutions: topical diclofenac solution (1.5% wt/wt diclofenac sodium in a carrier containing DMSO [45.5% wt/wt], propylene glycol, glyc erin, ethanol and water [Pennsaid, Dimethaid Health Care Ltd.]); a vehicle-control solution consisting of the complete carrier, including DMSO (45.5% wt/wt), but no diclofenac; and a placebo solution consisting of a modified carrier with a token amount of DMSO (4.5% wt/wt) for blinding purposes but no diclofenac. A randomization list, computer-generated by an outside statistician, specified 60 patients per site in sub-blocks of 6; a list was later provided for an additional potential 20 patients per site at the first 3 sites. To ensure complete blinding, the randomization sequence was concealed from the investigators, support staff, patients and anyone directly involved in conducting the study, until final data lock. The study kits were prepared, labelled and numbered independently by the sponsor’s quality assurance department. The 3 study solutions were identical clear, colourless liquids in opaque bottles; the labels differed only in patient identification number. The low concentration of DMSO in the placebo solution masked the garlic-like taste or odour sometimes reported with DMSO use. Patients applied 40 drops of solution (about 1.3 mL) around the affected knee (10 drops to each side: front, back, medial and lateral), without rubbing, 4 times daily for 28 days. Compliance was verified by weighing bottles at the start of each weekly visit and calculating the number of grams applied per day per knee. Both knees were treated if painful and evaluated for treatment safety, but efficacy analysis was performed on data for only the designated study knee, which had the greater baseline pain score.

Patients completed a WOMAC assessment daily and a patient global assessment (PGA) weekly. The WOMAC LK3.0 Osteoarthritis Index is a validated, multidimensional questionnaire of defined reliability, content, construct validity and responsiveness.21,22 It consists of 24 questions (5 on pain, 17 on physical function and 2 on stiffness), each scored on a 5-point Likert scale (0 to 4, 0 representing none). The PGA was scored from 0 to 4 (0 representing very good). Compassionate use of acetaminophen (up to two 325-mg tablets 4 times daily) was permitted for other body pain or residual knee pain throughout the washout and study periods, except during the 24 hours immediately before the baseline and final WOMAC assessments.

At the screening and final visits the patients provided urine and blood samples for routine analysis. Adverse events were recorded daily by the patients. In addition, at each weekly visit the investigator enquired about a checklist of gastrointestinal complaints commonly attributed to oral NSAID therapy. The knees were dermatologically assessed weekly; if erythema with induration was observed, the patient was withdrawn from the study. After the treatment period, the first 145 patients were tested for sensitization to their study solution (allergic contact dermatitis).26 The primary efficacy variable was the change from baseline to final assessment in the WOMAC subscale score for pain. Secondary variables were changes from baseline to final assessment in the WOMAC subscale scores for physical function and stiffness, as well as the PGA (sum of weekly scores). This core set of outcome measures follows the recommendations of the Outcome Measures in Arthritis Clinical Trials (OMERACT) III,27 the Osteoarthritis Research Society (OARSI)28 and the Group for the Respect of Ethics and Excellence in Science (GREES).29 Pain on walking (the first question of the WOMAC pain dimension) was analyzed a posteriori as a separate efficacy variable. The time course of pain relief was investigated for patients who responded to topical diclofenac treatment; responders were defined on the basis of the new OMERACT–OARSI set of responder criteria.30 A sample size of 40 patients per group was required to detect a difference between 2 treatment arms of 3 (standard deviation [SD] 5.0), 4 (SD 6.5) or 5 (SD 8.0) in the change in the WOMAC pain subscale score, with a power of 80% and a type 1 (α) error rate of 0.05 in a 2-tailed test. Enrolment was planned for 50 patients per treatment group to allow for nonevaluable patients.

The intent-to-treat analysis group consisted of all randomly assigned, treated patients that met critical inclusion criteria of primary osteoarthritis (radiologic abnormalities and pain after washout of prior therapy). Some investigators failed to collect baseline WOMAC data for some patients after washout (pain data for 29 patients, physical function and stiffness data for 77 patients); day 1 data were substituted for the missing baseline data. To ensure sufficient power for subgroup analysis for the patients with complete baseline data, enrolment was increased to 80 patients per group. For any other missing WOMAC data, the last observation was carried forward. There was no imputation of safety data.

Baseline demographic variables, acetaminophen consumption, radiologic scores and compliance were analyzed by means of the χ² test, Fisher’s exact test or analysis of variance, as appropriate. Change in each WOMAC subscale score (final minus baseline) was analyzed by means of analysis of covariance, with the baseline score as a covariate. PGA was analyzed by means of analysis of variance. All statistical tests were 2-sided and performed at the 0.05 level of significance.

Results

Of the 267 patients screened for the study 19 were excluded (5 were ineligible and 14 refused to participate). The remaining 248 were randomly assigned to treatment with 1 of the 3 study solutions (Fig. 1), and all of them received the allocated intervention. The baseline demographic characteristics of these 248 patients did not differ significantly between the treatment groups (Table 1). Of the patients in the topical diclofenac group 38% had bilateral knee pain and treated both knees, as compared with 49% (p = 0.17) of those in vehicle-control group and 51% (p = 0.09) of those in the placebo group. Radiographic analysis showed no significant difference between the treatment groups in the distribution of severity of joint-space narrowing and marginal osteophytes, respectively, within each knee compartment (lateral, p = 0.72 and 0.93; medial, p = 0.67 and 0.47; patello-femoral, p = 0.36 and 0.62). Compliance did not differ sig-
nificantly between the treatment groups; the topical diclofenac group applied 95% (5.4 g/knee) of the planned dose of solution daily. Reasons for withdrawal from the trial (by 10, 14 and 15 patients in the topical diclofenac, vehicle-control and placebo groups, respectively) are given in Fig. 1.

Data for 1 patient in the vehicle-control group were excluded from the intent-to-treat analysis, in accord with the International Conference on Harmonisation (ICH) guidelines, because of failure to meet the major entry criterion of primary osteoarthritis (the patient had an injury to the anterior cruciate ligament). Seven patients did not answer the PGA question; their data were excluded from the PGA analysis.

For the primary efficacy variable, pain, the mean change (and 95% confidence interval [CI]) from baseline to final assessment was significantly greater with topical diclofenac treatment (–3.9 [–4.8 to –2.9]; p = 0.023) than with vehicle-control (–2.5 [–3.3 to –1.7]; p = 0.016) treatment. For the secondary variables treatment with topical diclofenac solution was also superior to the vehicle-control and placebo solutions, leading to mean changes of –11.6 (–14.7 to –8.4; p = 0.002 and 0.014, respectively) in physical function, –1.5 (–1.9 to –1.1; p = 0.015 and 0.002, respectively) in stiffness and –0.8 (–1.1 to –0.6; p = 0.003 and 0.015, respectively) in pain on walking, and to a significantly better mean PGA score (p = 0.039 and 0.025, respectively) (Table 2). Using analysis of covariance, with baseline score and number of knees treated as covariates, we found no influence of bilateral knee pain on the significance of these efficacy results. Among defined responders to topical diclofenac therapy the WOMAC pain score progressively declined during the first week of treatment, with a 42% reduction by the fourth day.

Mean acetaminophen consumption was lower in the topical diclofenac group (36.2 [SD 52.1] tablets) than in the vehicle-control (49.5 [SD 63.4]) and placebo (54.9 [SD 69.2]) groups, but the differences were not statistically significant.

The rate of patient dropout due to lack of effect was significantly lower in the topical diclofenac group (2/84 [2%]) than in the vehicle-control (8/80 [10%]; p = 0.05) and placebo (10/84 [12%]; p = 0.02) groups.

Minor skin dryness or flakiness at the application site was the most frequent adverse event, occurring in 36% (30/84), 14% (11/80) and 1% (1/84) of the patients in the topical diclofenac, vehicle-control and placebo groups, respectively (Table 3). All skin reactions resolved promptly.

---

**Fig. 1: Flow of patients through the study.** R = randomization, AE = adverse event.
upon withdrawal of treatment. No significant difference was noted in the incidence of gastrointestinal events. The rate of dropout due to a related adverse event was 6% (5/84) in the topical diclofenac group, as compared with 4% (3/80; \( p = 0.72 \)) in the vehicle-control group and 0% (0/84; \( p = 0.06 \)) in the placebo group. Testing for allergic contact dermatitis yielded negative results in 53/53, 46/47 and 45/45 of the patients in the respective 3 groups.

A minor elevation in the serum level of alanine aminotransferase or aspartate aminotransferase, or both, was observed in 2 patients in the topical diclofenac group, 4 patients in the vehicle-control group and 1 patient in the placebo group. The elevation exceeded 1.2 times the upper limit of normal only when both levels were elevated (Table 4).

Table 1: Baseline demographic characteristics of patients with osteoarthritis of the knee, by study group

| Characteristic                  | Topical diclofenac n = 84 | Vehicle-control* n = 80 | Placebo† n = 84 |
|--------------------------------|---------------------------|-------------------------|-----------------|
| Female, no. (and %)            | 52 (62)                   | 54 (68)                 | 51 (61)         |
| Age, mean (SD), yr             | 62.5 (11.7)               | 62.1 (11.4)             | 60.8 (11.4)     |
| Weight, mean (SD), kg          | 81.3 (16.4)               | 83.9 (21.6)             | 84.8 (18.5)     |
| Height, mean (SD), m           | 1.65 (0.11)               | 1.65 (0.11)             | 1.67 (0.09)     |
| Patients treating 2 knees, no. (and %) | 32 (38)                   | 39 (49)                 | 43 (51)         |

Note: SD = standard deviation.
* Patients used a solution with the same carrier as in topical diclofenac solution (containing dimethyl sulfoxide [DMSO]) but no diclofenac.
† Patients used a solution with a modified carrier (containing a token amount of DMSO for blinding purposes) but no diclofenac.

Table 2: Efficacy-variable measures in the intent-to-treat group after 4 weeks of treatment

| Variable; measurement | Topical diclofenac n = 84 | Vehicle-control n = 79 | Placebo n = 84 |
|-----------------------|---------------------------|-------------------------|----------------|
| WOMAC LK3.0 Osteoarthritis Index* |                           |                         |                |
| Pain                  |                           |                         |                |
| Baseline, mean (SD)   | 9.1 (3.5)                 | 9.3 (3.5)               | 9.4 (3.6)      |
| Final, mean (SD)      | 5.2 (4.6)                 | 6.8 (4.8)               | 6.9 (4.5)      |
| Change, mean (95% CI) | -3.9 (-4.8 to -2.9)‡§     | -2.5 (-3.3 to -1.7)     | -2.5 (-3.3 to -1.7) |
| % change from baseline| -42.9                     | -26.9                   | -26.6          |
| Physical function     |                           |                         |                |
| Baseline, mean (SD)   | 29.5 (13.7)               | 30.5 (11.9)             | 30.9 (13.1)    |
| Final, mean (SD)      | 17.9 (15.6)               | 24.7 (16.2)             | 23.7 (15.9)    |
| Change, mean (95% CI) | -11.6 (-14.7 to -8.4)¶   | -5.7 (-8.3 to -3.2)     | -7.1 (-9.3 to -4.4) |
| % change from baseline| -39.3                     | -18.7                   | -23.0          |
| Stiffness             |                           |                         |                |
| Baseline, mean (SD)   | 3.7 (1.7)                 | 3.5 (1.7)               | 3.7 (1.8)      |
| Final, mean (SD)      | 2.2 (1.9)                 | 2.7 (2.0)               | 3.0 (1.9)      |
| Change, mean (95% CI) | -1.5 (-1.9 to -1.1)‡**    | -0.7 (-1.2 to -0.3)     | -0.6 (-1.0 to -0.2) |
| % change from baseline| -40.5                     | -20.0                   | -16.2          |
| Pain on walking       |                           |                         |                |
| Baseline, mean (SD)   | 1.8 (1.0)                 | 1.9 (0.9)               | 2.0 (0.9)      |
| Final, mean (SD)      | 1.0 (1.0)                 | 1.5 (1.1)               | 1.4 (1.0)      |
| Change, mean (95% CI) | -0.8 (-1.1 to -0.6)¶     | -0.4 (-0.6 to -0.2)     | -0.6 (-0.8 to -0.4) |
| % change from baseline| -44.4                     | -21.1                   | -30.0          |
| Patient global assessment† |                         |                         |                |
| Sum, mean (95% CI)    | 6.7 (6.1 to 7.4)††        | 7.8 (6.9 to 8.6)        | 7.8 (7.2 to 8.5) |

Note: WOMAC = Western Ontario and McMaster Universities, CI = confidence interval.
*Subscales scored as follows, 0 representing none: pain, 0 to 20; physical function difficulty, 0 to 68; stiffness, 0 to 8; and pain on walking, 0 to 4.
† Scored from 0 to 4, 0 representing very good. The scores for weeks 1, 2, 3 and 4 were summed (maximum summed score is 16).
‡ p < 0.05 and § p < 0.01 compared with the value for the vehicle-control solution group.
¶ p < 0.05 and ‡ p < 0.01 compared with the value for the placebo group.
†† p < 0.05 compared with the values for the 2 other groups.
Interpretation

We have shown that 4 weeks of treatment with this topical diclofenac solution relieved the symptoms of primary knee osteoarthritis significantly better than the vehicle-control or placebo solution. The WOMAC subscale scores improved 42.9% for pain, 39.3% for physical function, 40.5% for stiffness and 44.4% for pain on walking. Among the responders to topical diclofenac therapy (those meeting OMERACT-OARSI criteria\textsuperscript{30}), rapid onset of pain relief was observed during the first week of treatment. The primary adverse effects noted were reversible application-site skin reactions, predominantly dryness. The low rate of dropout due to related adverse events (6%) in the topical diclofenac group, despite the prohibition of emollient use, suggests that these were tolerable, minor reactions.

Comparison of our efficacy results with those from previously published trials of topical NSAID treatment of osteoarthritis is difficult, as the latter were shorter and used different outcome measures.\textsuperscript{10,11,14,15} One placebo-controlled trial investigating 2 weeks of treatment of knee osteoarthritis with a topical diclofenac gel was conducted with the use of the WOMAC and found reductions in pain, physical function and stiffness of 37%, 26% and 17%, respectively.\textsuperscript{12} The design of our study more closely parallels that of oral diclofenac therapy.\textsuperscript{38} Even prolonged exposure to large topical doses of DMSO (1 g/kg daily for up to 3 months) rarely produced enzyme elevations.\textsuperscript{19} For comparison, in this study a 60-kg person who applied diclofenac solution to both knees received only 0.06 g/kg of DMSO daily.

Although oral treatment with diclofenac can result in elevated serum levels of liver enzymes, only 1 patient using topical diclofenac in this study exhibited an elevation in alanine aminotransferase or aspartate aminotransferase that exceeded 1.2 times the upper limit of normal. Blood levels of diclofenac are up to 125 times lower with this topical solution (12 ng/mL)\textsuperscript{37} than those reported with standard oral diclofenac therapy.\textsuperscript{38} Even prolonged exposure to large topical doses of DMSO (1 g/kg daily for up to 3 months) rarely produced enzyme elevations.\textsuperscript{19} For comparison, the trial length of 4 weeks may not be long enough to assess potential long-term safety concerns, particularly for the gastrointestinal system. Although comparing our efficacy results with those for reported trials of oral diclofenac therapy is justified, because the study design and outcome measures were similar, a direct-equivalence trial is required to fully assess the relative effects of the 2 types of treatment.

Table 3: Adverse events

| Adverse event   | Patient group; no. (and %) of patients* |
|-----------------|----------------------------------------|
|                 | Topical diclofenac n = 84 | Vehicle-control n = 80 | Placebo n = 84 |
| comp. At application site |  |  |  |
| Dry skin        | 30 (36)† ‡ | 11 (14)§ | 1 (1) |
| Paresthesia     | 12 (14) | 18 (22)§ | 5 (6) |
| Rash            | 11 (13)¶ | 6 (8) | 3 (4) |
| Pruritus        | 9 (11) | 6 (8) | 3 (4) |
| Gastrointestinal and other |  |  |  |
| Constipation    | 1 (1) | 1 (1) | 1 (1) |
| Diarrhea        | 1 (1) | 2 (2) | 3 (4) |
| Dyspepsia       | 6 (7) | 4 (5) | 5 (6) |
| Nausea          | 0 | 4 (5) | 1 (1) |
| Vomiting        | 0 | 1 (1) | 1 (1) |
| Halitosis       | 4 (5) | 1 (1) | 0 |
| Body odour      | 2 (2) | 0 | 0 |

*Some patients described several events or described a single event with several terms. \(\dagger p < 0.0001, \ddagger p < 0.05, \| p < 0.01\) compared with the value for the placebo group.

Table 4: Occurrence of elevated serum liver enzyme values

| Increased enzyme value | Patient group; no. of patients* |
|------------------------|---------------------------------|
|                         | Topical diclofenac n = 82 | Vehicle-control n = 74 | Placebo n = 75 |
| ALT and AST            | 1† | 2† | 0 |
| ALT only               | 0 | 2 | 0 |
| AST only               | 1 | 0 | 1 |

Note: ALT = alanine aminotransferase; AST = aspartate aminotransferase.

*Includes patients whose values changed from within the normal range before the study to above normal with treatment (all values were 2.5 times the upper limit of normal). Patients without baseline or final laboratory data are excluded.

†The increase was 1.2 times the upper limit of normal.

We have shown that 4 weeks of treatment with this topical diclofenac solution relieved the symptoms of primary knee osteoarthritis significantly better than the vehicle-control or placebo solution. The WOMAC subscale scores improved 42.9% for pain, 39.3% for physical function, 40.5% for stiffness and 44.4% for pain on walking. Among the responders to topical diclofenac therapy (those meeting OMERACT-OARSI criteria\textsuperscript{30}), rapid onset of pain relief was observed during the first week of treatment. The primary adverse effects noted were reversible application-site skin reactions, predominantly dryness. The low rate of dropout due to related adverse events (6%) in the topical diclofenac group, despite the prohibition of emollient use, suggests that these were tolerable, minor reactions.

Comparison of our efficacy results with those from previously published trials of topical NSAID treatment of osteoarthritis is difficult, as the latter were shorter and used different outcome measures.\textsuperscript{10,11,14,15} One placebo-controlled trial investigating 2 weeks of treatment of knee osteoarthritis with a topical diclofenac gel was conducted with the use of the WOMAC and found reductions in pain, physical function and stiffness of 37%, 26% and 17%, respectively.\textsuperscript{12} The design of our study more closely parallels that of oral NSAID trials, including its being a large, randomized controlled trial with appropriate power, standardized radiologic and clinical entry criteria, and use of outcome measures standardized at OMERACT III as essential in osteoarthritis trials.\textsuperscript{27} Several reported investigations of oral diclofenac treatment for knee osteoarthritis have used the WOMAC. The percentage improvement in WOMAC subscale scores that we observed with topical diclofenac therapy (39.3% to 44.4%) are similar to those reported for oral diclofenac treatment (35% to 40%).\textsuperscript{12,31}

The topical diclofenac formulation developed for this study contained DMSO,\textsuperscript{44} which enhances the in vitro percutaneous absorption of diclofenac.\textsuperscript{11} Some of the adverse events in this study, particularly halitosis and body odour, can be attributed to the DMSO. DMSO is metabolized to the volatile gas dimethyl sulfide, which produces a garlic-like odour or taste when expired. The skin reactions, such as dry skin, appear to be due to the cutaneous presence of both DMSO and diclofenac. Although unsubstantiated claims of therapeutic efficacy for DMSO have been made,\textsuperscript{46} all efficacy variable comparisons in this study showed no therapeutic benefit of the vehicle-control solution (containing 45.5% DMSO) over the placebo solution (containing 4.5% DMSO).

Although oral treatment with diclofenac can result in elevated serum levels of liver enzymes, only 1 patient using topical diclofenac in this study exhibited an elevation in alanine aminotransferase or aspartate aminotransferase that exceeded 1.2 times the upper limit of normal. Blood levels of diclofenac are up to 125 times lower with this topical solution (12 ng/mL)\textsuperscript{37} than those reported with standard oral diclofenac therapy.\textsuperscript{38} Even prolonged exposure to large topical doses of DMSO (1 g/kg daily for up to 3 months) rarely produced enzyme elevations.\textsuperscript{19} For comparison, in this study a 60-kg person who applied diclofenac solution to both knees received only 0.06 g/kg of DMSO daily.

One limitation of our study is the use of day-1 efficacy scores for some patients missing baseline scores. After excluding the data for those patients (which left data for 218 patients in the pain subset and 170 in the physical-function and stiffness subsets), we found no effect on the conclusion of superiority of topical diclofenac therapy over vehicle-control treatment (pain, \(p = 0.009\); physical function, \(p = 0.002\); stiffness, \(p = 0.023\) and placebo treatment (pain, \(p = 0.004\); physical function, \(p = 0.004\); stiffness, \(p = 0.004\)). Other limitations relate to study design. The trial length of 4 weeks may not be long enough to assess potential long-term safety concerns, particularly for the gastrointestinal system. Although comparing our efficacy results with those for reported trials of oral diclofenac therapy is justified, because the study design and outcome measures were similar, a direct-equivalence trial is required to fully assess the relative effects of the 2 types of treatment.
This randomized controlled trial has provided strong evidence for the efficacy and safety of this topica docusate sodium solution. Future trials of greater treatment duration and a head-to-head comparison with oral NSAID therapy are required to address long-term safety and provide evidence of the efficacy and safety of this product in relation to standard therapies. None the less, the current practice guidelines, this topica NSAID treatment is a reasonable new option for the management of osteoarthritis of the knee.

This article has been peer reviewed.

From the Division of Rheumatology, University Health Network, Western Division, University Health Network, Toronto, Ont. (Bookman), and Dimethaid Health Care Ltd., Markham, Ont. (Williams, Shainhouse)

Competing interests: None declared for Arthur Bookman. Kate Williams and Zev Shainhouse were employees of Dimethaid Health Care Ltd. (as clinical research associate and medical director, respectively) when the study was conducted.

Contributors: Arthur Bookman, the principal investigator, contributed to patient recruitment, data acquisition and interpretation, and manuscript revision. Kate Williams supervised study conduct and data management and analysis; she also re-visited the manuscript to study design and to data analysis and interpretation; he drafted and revised the manuscript. All authors approved the version of the manuscript to be published.

Acknowledgements: We acknowledge the collaboration and commitment of all study investigators and support staff, without whom the study would not have been possible: Philip A. Baer, Scarborough, Ont.; David C. Hoag, Peterborough, Ont.; Robert F. Herman, Blossom halls, Ont.; Noel A. Kere, Pontiac, Ont.; Gordon D. Ko, Markham, Ont.; Peter R. Welsh, Toronto, Ont.; and D. Paul Willoughby, Woodstock, Ont. We also thank Lisa M. Thomas, Dimethaid Health Care Ltd., for help in preparing the manuscript.

References

1. Felton DT, Lawrence RC, Dieppe PA, Hirsch R, Helcim C, Jordan JM, et al. Osteoarthritis: new insights: Part 1. The disease and its risk factors. Ann Intern Med 2000;133:635–46.
2. Gabriel SE, Jakkiniminen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96.
3. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99.
4. Whelan A. Nephrotoxicity of non-steroidal anti-inflammatory drugs: physiological and pharmacological correlation. J Am Soc Nephrol 1999;10:195-203.
5. Bombardier C, Laine L, Reinc A, Shapiro D, Burgos-Vargas R, David B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-28.
6. Silverstein FE, Feach-Goldsmith J, Simon LS, Pincus T, Whelan A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-57.
7. Lang B, Jensen DM, Watson DJ, Harper SE, Zhao PH, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
8. Irrer DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibitors. Am J Med 1999;107 (Suppl 6A):658-708.
9. Mulherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
10. Dreiser RL, Tsim-Camus M. DHEP plasters as a topical treatment of knee osteoarthritis - a double-blind placebo-controlled study. Drugs Exp Clin Res 1991;19:117-23.
11. Roth SH. A controlled clinical investigation of 3% docusate sodium 2.5% sodium hyaluronate topical gel in the treatment of inflamed joint pain in chronic oral NSAID users with osteoarthritis. Int J Tissue Res 1993;15:129-32.
12. Grace D, Rogers J, Sheik K. Osteoarthritis topical docusate sodium versus placebo: a double-blind, randomized clinical trial in patients with osteoarthritis of the knee. J Rheumatol 1999;26:2665-69.
13. Moore RA, Tramer MR, Carroll D, Wiffers PJ, McQuay HJ. Quantitative systematic review of topicaly applied non-steroidal anti-inflammatory drugs. BMJ 1999;318:34-8.
14. Rosensten ED. Topical agents in the treatment of rheumatic disorders. Rheum Dis Clin North Am 1999;25:899-918.

15. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drug 2000;60:555-74.
16. Evans JMM, McMahon A, McGilchrist M, White G, Murray F, McDevitt D. The clinical management of non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 1995;311:22-6.
17. Scott DL, Shiplep M, Dawson A, Edwards S, Symmons DPM, Woolf AD. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. Br J Rheumatol 1998;37:546-54.
18. American College of Rheumatology. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15.
19. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlana JW, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55.
20. Altman RD. Criteria for classification of clinical osteoarthritis. J Rheumatol 1991;18(Suppl 27):10-2.
21. Kellgren JH. The epidemiology of chronic rheumatism. Vol. II. Atlas of standard radiographs of arthritis. Oxford: Blackwell Scientific Publications; 1963.
22. Bellamy N. WOMAC osteoarthritis index - a user’s guide. London (ON): London Health Sciences Centre; 1995.
23. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt L. Validation study of WOMAC: a health status instrument for measuring clinically-important patient-relevant outcomes following total hip or knee arthroplasty in os- troarthritis. J Orthop Rheumatol 1988;1:95-108.
24. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in pa- tients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1831-40.
25. Bellamy N. Osteoarthritis clinical trials: candidate variables and clinimetric properties. J Rheumatol 1997;24:768-78.
26. Marzulli FN, Maibach HI. Contact allergy: predictive testing in humans. In: Dermatoxontology and pharmacology. Advance in modern toxicology. Vol 4. Washington (DC): Hemisphere Publishing; 1977. p. 335-72.
27. Bellamy N, Curbon J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT-III. J Rheumatol 1997;24:799-802.
28. Altman RD, Branch K, Hochberg M, Moskwitze R. Design and conduct of clini- cal trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilege 1996;4:217-43.
29. Group for the Respect of Ethics and Excellence in Science (GROESS), Os- teoarthritis Section. Recommendations for the registration of drugs used in the treatment of osteoarthritis. Ann Rheum Dis 1996;55:52-7.
30. Pham T, van der Heijde D, Lasserre M, Altman RD, Anderson JF, Bellamy N, et al. Outcome variables for osteoarthritis clinical trials: the OMERACT- OARSI set of responder criteria. J Rheumatol 2003;30:1648-54.
31. Statistical principles for clinical trials. ICH harmonised tripartite guidance E9. Geneva: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 1998. Available: www.ich.org/MediaServer.jsrt?@_ID=485&@_MODE=GLB (accessed 2004 May 25).
32. Yocum D, Fleischmann R, Dalgin P, Caldwell J, Hall D, Roszkos P. Safety and efficacy of meloxicam in the treatment of osteoarthritis. Arch Intern Med 2000;160:2947-54.
33. McKenna F, Borenstein D, Wendi H, Wallmark C, Lekfowich JB, Gies GS. Celecoxib versus docusate in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-19.
34. Kligman AM. Topical pharmacology and toxicology of dimethyl sulfoxide - Part 1. JAMA 1963;193:796-804.
35. Hewitt PG, Polnate N, Wester RC, Maibach HI, Shainhouse JZ. In vivo cutaneous disposition of a topical docusate lotion in human skin: effect of a multi-dose regimen. Pharm Res 1998;15:988-92.
36. Council on scientific affairs, American Medical Association. Dimethyl sulfoxide: controversy and current status - 1981. JAMA 1992;248:1369-71.
37. Hui X, Hewitt PG, Polnate N, Maibach HI, Shainhouse JZ, Wester RC. In vivo bioavailability and metabolism of topical docusate lotion in human vol- unteers. Pharm Res 1998;15:1589-95.
38. Voluntary product monograph. In: Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. Ottawa (ON): The Association; 2004. p. 2203-4.
39. Brolyn RD. The human toxicology of dimethyl sulfoxide. Ann N Y Acad Sci 1975;24:497-506.

Correspondence to: Dr J. Zev Shainhouse, Dimethaid Health Care Ltd., 1405 Denison St., Markham ON L3R 5V2, fax 905 415-0827